AasM, MelleI, BettellaF, et al.Psychotic patients who used cannabis frequently before illness onset have higher genetic predisposition to schizophrenia than those who did not. Psychol Med, 2018; 48(1):43–49; doi: 10.1017/S0033291717001209
2.
AlessiN, AlkhouriI, FluentT, et al.Haloperidol decanoate in children. J Am Acad Child Adolesc Psychiatry, 2001; 40(8):865–866; doi:10.1097/00004583-200108000-00002
3.
BaezaI, ForteaA, IlzarbeD, et al.What role for long-acting injectable antipsychotics in managing schizophrenia spectrum disorders in children and adolescents? A systematic review. Paediatr Drugs, 2023; 25(2):135–149; doi:10.1007/s40272-023-00558-x
4.
BenarousX, LahayeH, CottinG, et al.Trends in the use of long-acting injectable antipsychotics in children and adolescents in France between 2014 and 2018. Schizophr Res, 2022; 248:231–232; doi:10.1016/j.schres.2022.09.003
5.
CorrellCU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry, 2008; 69Suppl 4:26–36.
6.
DiMascioA, BernardoDL, GreenblattDJ, et al.A controlled trial of amantadine in drug-induced extrapyramidal disorders. Psychopharmacol Bull, 1977; 13(3):31–33.
7.
ForteaA, IlzarbeD, EspinosaL, et al.Long-acting injectable atypical antipsychotic use in adolescents: An observational study. J Child Adolesc Psychopharmacol, 2018; 28(4):252–257; doi: 10.1089/cap.2017.0096
8.
GuptaN, GuptaM, EsangM. Lost in translation: Challenges in the diagnosis and treatment of early-onset schizophrenia. Cureus, 2023; 15(5):e39488; doi: 10.7759/cureus.39488
9.
JacobP, ShereS, KommuJVS. The use of first-generation long-acting injectable antipsychotics in children and adolescents—A retrospective audit from India. Asian J Psychiatr, 2021; 61:102663; doi: 10.1016/j.ajp.2021.102663
10.
KaneJM, SchoolerNR, MarcyP, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: A randomized clinical trial [published correction appears in JAMA Psychiatry. 2020 Dec 1;77(12):1310]. JAMA Psychiatry 2020;77(12)(12):1217–1224; doi: 10.1001/jamapsychiatry.2020.2076
11.
KellyJT, ZimmermannRL, AbuzzahabFS, et al.A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism. Pharmacology, 1974; 12(2):65–73; doi: 10.1159/000136523
12.
KhokharJY, DwielLL, HenricksAM, et al.The link between schizophrenia and substance use disorder: A unifying hypothesis. Schizophr Res, 2018; 194:78–85; doi: 10.1016/j.schres.2017.04.016
13.
Lopez-MorinigoJD, LeuchtS, ArangoC. Pharmacological treatment of early-onset schizophrenia: A critical review, evidence-based clinical guidance and unmet needs. Pharmacopsychiatry, 2022; 55(5):233–245; doi: 10.1055/a-1854-0185
14.
LytleS, McVoyM, SajatovicM. Long-acting injectable antipsychotics in children and adolescents. J Child Adolesc Psychopharmacol, 2017; 27(1):2–9; doi: 10.1089/cap.2016.0055
15.
ModesittT, KubascikE, OttC. Extent of use of long-acting injectable antipsychotics in children and adolescents within Indiana Medicaid. Ment Health Clin, 2018; 8(5):202–207; doi: 10.9740/mhc.2018.09.202
16.
SilverH, GeraisyN. No difference in the effect of biperiden and amantadine on negative symptoms in medicated chronic schizophrenic patients. Biol Psychiatry, 1995; 38(6):413–415; doi: 10.1016/0006-3223(95)00231-5
17.
VecellioM, SchopperC, ModestinJ. Neuropsychiatric consequences (atypical psychosis and complex-partial seizures) of ecstasy use: Possible evidence for toxicity-vulnerability predictors and implications for preventative and clinical care. J Psychopharmacol, 2003; 17(3):342–345; doi: 10.1177/02698811030173018
